Prot#16-1542: Phase II Study of Ruxolitinib in Relapsed or Refractory T-cell Lymphomas

Project: Research project

Project Details

StatusActive
Effective start/end date3/29/22 → 3/29/27

Funding

  • Memorial Sloan-Kettering Cancer Center (Prot#16-1542 // Prot#16-1542)
  • Incyte Corporation (Prot#16-1542 // Prot#16-1542)